Plate Nº 58 · recorded November 13, 2026
Health & Medicine ResearchReported finding
Three Antidepressants May Beat Prozac at Keeping Depression Away
An analysis of 115 trials with over 30,000 people found escitalopram, agomelatine and duloxetine beat fluoxetine at sustaining recovery from depression long-term.
By Elena Vasquez3 min read525 words
In brief
- Researchers analyzed 115 randomized clinical trials with more than 30,000 participants.
- The review compared 20 antidepressants and was published in The Lancet Psychiatry.
- Escitalopram, agomelatine and duloxetine outperformed fluoxetine on long-term effectiveness.
- Agomelatine carries a risk of liver injury and requires appropriate monitoring.
- Patients doing well on an existing medicine should not switch based on this study alone.
Three drugs — escitalopram, agomelatine and duloxetine — performed better than fluoxetine at keeping depression from coming back, according to a large international review of 115 clinical trials published in The Lancet Psychiatry.
The analysis covered more than 30,000 participants and compared 20 antidepressants. Researchers looked at two things: how well each drug improved symptoms in the first weeks, and how well it sustained that response during longer-term treatment. The differences showed up on the second measure. That distinction matters, because choosing an antidepressant may involve more than finding a medicine that helps quickly.
The takeaway: some medicines seem better than others at helping people recover and stay well over time.
What did the study actually measure?
The team pooled results from 115 randomized clinical trials — the gold standard for testing treatments, where patients are randomly assigned to a drug or a comparison option. By combining so many studies, the researchers could compare 20 antidepressants on both short-term improvement and long-term staying power.
Large comparisons like this can reveal patterns that single trials miss. Individual studies are often too small to distinguish between drugs.
The catch: the included trials differed in participants, duration and methods. Comparisons drawn across separate trials carry uncertainty. A ranking, the researchers stressed, is not a guarantee of success for any individual patient.
How do these three drugs work?
They are not interchangeable, and their chemistry differs in ways that may matter for treatment choices.
- Escitalopram is a selective serotonin reuptake inhibitor (SSRI) — a widely prescribed class that boosts serotonin, a chemical messenger involved in mood.
- Duloxetine acts on two messengers, serotonin and noradrenaline.
- Agomelatine works through a different mechanism altogether, involving melatonin and serotonin signaling. It also carries a risk of liver injury and requires appropriate monitoring.
Depression itself affects mood, sleep, concentration, energy and the ability to manage everyday activities. Even when symptoms improve, some people relapse. Continuing medication for an appropriate period reduces that risk, though the best approach varies with personal circumstances.
Should patients switch medications?
No — at least not on the strength of this analysis alone. The researchers emphasized that stronger average performance does not make one drug the best choice for everyone.
People respond differently. Side effects, other health conditions, interactions with other medicines and previous treatment experiences all shape the right choice. Someone doing well on an existing medicine should not assume they need to change it because of this study.
The findings may eventually inform treatment guidelines, particularly when clinicians and patients weigh short-term relief against prevention of future episodes.
What should people on antidepressants do now?
Talk to the prescriber — don't stop on their own. Withdrawal symptoms and a return of depression can occur when medicines are changed without a plan.
Good decisions are shared decisions, the researchers indicated, weighing:
- what has already worked for the person,
- how well side effects are tolerated,
- the patient's own preferences,
- evidence from large studies like this one.
The practical message is simple: effective depression care looks beyond the first response. The goal is not only to feel better, but to find a safe, sustainable treatment plan that supports lasting recovery.
via knowridge.com (Source)
More from Elena Vasquez
Show full bio
Correspondent covering money, funding and market shifts around general science news at SciBeat.
405 articles
Nearby plates
- Alzheimer's Drug Matches Trial Results in Real-World Patients
- Short-Acting Psychedelic Tested Against Major Depression in Phase IIa Trial
- Blood pressure medicines protect less when doses are missed
- One Year After Ibogaine, Veterans Still See Relief From PTSD
- Brain scans reveal shrinkage in treatment-resistant schizophrenia